Geode Capital Management’s Tarsus Pharmaceuticals TARS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $37.9M | Buy |
934,420
+68,986
| +8% | +$2.8M | ﹤0.01% | 1577 |
|
|
2025
Q1 | $44.5M | Buy |
865,434
+26,630
| +3% | +$1.37M | ﹤0.01% | 1437 |
|
|
2024
Q4 | $46.5M | Buy |
838,804
+3,014
| +0.4% | +$167K | ﹤0.01% | 1482 |
|
|
2024
Q3 | $27.5M | Buy |
835,790
+62,555
| +8% | +$2.06M | ﹤0.01% | 1809 |
|
|
2024
Q2 | $21M | Buy |
773,235
+143,543
| +23% | +$3.9M | ﹤0.01% | 1907 |
|
|
2024
Q1 | $22.9M | Buy |
629,692
+19,956
| +3% | +$726K | ﹤0.01% | 1848 |
|
|
2023
Q4 | $12.3M | Buy |
609,736
+83,476
| +16% | +$1.69M | ﹤0.01% | 2217 |
|
|
2023
Q3 | $9.35M | Buy |
526,260
+81,399
| +18% | +$1.45M | ﹤0.01% | 2310 |
|
|
2023
Q2 | $8.04M | Buy |
444,861
+95,712
| +27% | +$1.73M | ﹤0.01% | 2422 |
|
|
2023
Q1 | $4.39M | Buy |
349,149
+7,958
| +2% | +$100K | ﹤0.01% | 2690 |
|
|
2022
Q4 | $5M | Buy |
341,191
+11,710
| +4% | +$172K | ﹤0.01% | 2666 |
|
|
2022
Q3 | $5.64M | Buy |
329,481
+63,397
| +24% | +$1.09M | ﹤0.01% | 2605 |
|
|
2022
Q2 | $3.88M | Buy |
266,084
+135,326
| +103% | +$1.98M | ﹤0.01% | 2834 |
|
|
2022
Q1 | $2.2M | Buy |
130,758
+4,943
| +4% | +$83.1K | ﹤0.01% | 3215 |
|
|
2021
Q4 | $2.83M | Buy |
125,815
+2,117
| +2% | +$47.6K | ﹤0.01% | 3197 |
|
|
2021
Q3 | $2.67M | Sell |
123,698
-1,823
| -1% | -$39.3K | ﹤0.01% | 3233 |
|
|
2021
Q2 | $3.64M | Buy |
125,521
+23,712
| +23% | +$687K | ﹤0.01% | 3080 |
|
|
2021
Q1 | $3.28M | Sell |
101,809
-8,566
| -8% | -$276K | ﹤0.01% | 2998 |
|
|
2020
Q4 | $4.56M | Buy |
+110,375
| New | +$4.56M | ﹤0.01% | 2651 |
|